key: cord-313756-2pqpk3v7
authors: De Vriese, An S.; Reynders, Marijke
title: In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’
date: 2020-06-27
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2020.06.005
sha: 
doc_id: 313756
cord_uid: 2pqpk3v7

nan

In a small group of hemodialysis patients with confirmed SARS-CoV-2 infection, we reported that the presence of anti-SARS-CoV-2 IgG overlaps by several weeks with detectable viral RNA in the upper airways (1) . The core message of our communication is that this antibody response, while proof of recent exposure to SARS-CoV-2, should not be interpreted as prima facie evidence of immunity to the virus. Viral load was highest during the first week of illness, suggesting that patients are most infectious during this period. It remains unclear whether the lower viral loads during the following weeks associate with a clinically relevant transmissibility of SARS-CoV-2 requiring further quarantining. As also advocated by Dudreuilh and Moutzouris(2) and pending further evidence, we submit that the prudent approach is to await negative reverse transcriptase-polymerase chain reaction test results.

We measured anti-SARS-CoV-2 IgG with a N protein-based ELISA (NovaLisa, NovaTec). Dudreuilh and Moutzouris suggest that the combination with a S protein-based assay may provide additional information. We have repeated our analyses with a combined S1 

Financial Disclosure: The authors declare that they have no relevant financial interests.

Peer Review: Received June 20, 2020. Accepted June 24, 2020 after editorial review by an Associate Editor and a Deputy Editor.

IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis

De-isolation of COVID-19-positive hemodialysis patients in the outpatient setting: a single-center experience

Clinical performance of different SARS-CoV-2 IgG antibody tests